search
Back to results

Hypoproteic Diet in Acromegaly (IpoProAcro)

Primary Purpose

Acromegaly

Status
Not yet recruiting
Phase
Not Applicable
Locations
Italy
Study Type
Interventional
Intervention
Usual clinical practice + hypoproteic diet
Sponsored by
Azienda Ospedaliero Universitaria Maggiore della Carita
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Acromegaly

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Age 18/65
  • Diagnosis of Acromegaly
  • In therapy with somatostatin analogues

Exclusion Criteria:

  • pregnancy or lactation
  • alchool or drugs abuse
  • cancer
  • Hematological diseases

Sites / Locations

  • : Italy Pediatric Endocrine Service of AOU Maggiore della Carità of Novara; SCDU of Pediatrics, Department of Health Sciences, University of Eastern Piedmont

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Acromegalic adult in therapy with somatostatin analogues

Arm Description

Patients will continue the usual medical outpatient visits cadency and will keep the same pharmacological therapy throughout the whole duration of the study. Drugs have to include somatostatin analogues. At the same time, patients will be trained by an expert dietician in the habit of an isocaloric and hypoproteic diet and will come back at 2,4,6 and 8 weeks after T0 for all the necessary study assessments and compliance checking.

Outcomes

Primary Outcome Measures

Change in disease related hormones
Variation of GH, IGF-1, IGFBP1, IGFBP3 hormones

Secondary Outcome Measures

Change in weight
Variation of body weight assessed through body mass index change (BMI)(kg/m2)
Change in body circumferences
Variation of body circumferences (waist, hips)
Change in metabolic control
Change of cardio-metabolic risk factors: lipid profile
Change in metabolic control
Change of cardio-metabolic risk factors: insulin resistance (HOMA-IR)
Change in kidney profile
Variation of serum creatinin
Change in liver profile
Variation of liver markers(AST, ALT, GGT)
Change in uric acid
Variation of uric acid in blood through enzymatic determination
Change in body composition
Change of body composition (fat mass %) (BIVA)
Change in body composition
Change of body composition (fat mass %) (DXA)
Change in blood count
Variation of blood count
Change in microbiota
Variation of prevalence of microbiota phyla through DNA sequencing of stools
Change in omics profile
Variation of lipidomic profile of stools through liquid and gas chromatography
Change in omics profile
Variation of proteomic profile of stools through liquid and gas chromatography
Change in microvesicles
Variation of urinary microvesicles levels
Change in microvesicles
Variation of serum microvesicles levels
Change in basal metabolic rate
Variation of basal metabolic rate (kcal)

Full Information

First Posted
March 18, 2022
Last Updated
September 27, 2023
Sponsor
Azienda Ospedaliero Universitaria Maggiore della Carita
search

1. Study Identification

Unique Protocol Identification Number
NCT05298891
Brief Title
Hypoproteic Diet in Acromegaly
Acronym
IpoProAcro
Official Title
Deciphering the Role of a Low Protein Diet in Disease Control in Acromegalic Patients
Study Type
Interventional

2. Study Status

Record Verification Date
September 2023
Overall Recruitment Status
Not yet recruiting
Study Start Date
September 1, 2024 (Anticipated)
Primary Completion Date
December 1, 2025 (Anticipated)
Study Completion Date
March 1, 2026 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Azienda Ospedaliero Universitaria Maggiore della Carita

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Since protein and AAs are master regulator of GH and IGF-I secretion, we hypothesized that a low protein diet could reduce GH and IGF-I levels in acromegalic patients in addition to conventional therapy. Furthermore, we aim to explore metabolomic, microbiota, and micro-vesicle fingerprints of GH hypersecretion during conventional therapy and after a low protein diet
Detailed Description
Nutrients are crucial modifiers of the GH/IGF-I axis. In particular, a close cross-talk between proteins and amino acids (AAs) and GH/IGF-I secretion exists. Both AAs and proteins affect GH secretion. AAs stimulate GH secretion upon oral administration, with different potency among studies, being the combination of arginine and lysine the most powerful. Soy proteins also stimulate GH secretion when ingested either as hydrolysed proteins or free AAs. Furthermore, the acute GH response to AAs ingestion may be influenced by the daily amount of dietary protein/AAs consumption: diets high in proteins apparently increase basal GH levels. AAs and proteins have a positive effect on IGF-I secretion as well. In general, high levels of proteins, especially animal and dairy proteins, and consumption of branched chain amino acids (BCAAs) increase serum IGF-I levels. Considering pathological GH conditions, metabolomic analysis of acromegalic patients suggests that the main metabolic fingerprint of GH hypersecretion is a reduction in BCAAs, related to the disease activity. Moreover, there is evidence that GH, rather than IGF-I, is the main mediator of such metabolic fingerprint, which may be related to increased uptake of BCAAs by the muscles, increased gluconeogenesis, and raised consumption of BCAAs. Thus, in acromegaly, a tailored diet is a further strategy that may contribute to blunt GH/IGF-I secretion. Indeed, some authors recently suggested that "personalized" or "precision" nutrition in some conditions and diseases could have an impact on their phenotype, combining dietary recommendations with individual's genetic makeup, metabolic and microbiome characteristics, and environment. However, studies on precision nutrition in acromegaly are still in a neonatal era.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Acromegaly

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
12 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Acromegalic adult in therapy with somatostatin analogues
Arm Type
Experimental
Arm Description
Patients will continue the usual medical outpatient visits cadency and will keep the same pharmacological therapy throughout the whole duration of the study. Drugs have to include somatostatin analogues. At the same time, patients will be trained by an expert dietician in the habit of an isocaloric and hypoproteic diet and will come back at 2,4,6 and 8 weeks after T0 for all the necessary study assessments and compliance checking.
Intervention Type
Other
Intervention Name(s)
Usual clinical practice + hypoproteic diet
Intervention Description
Diet will be composed by: energy equal to daily energy expenditure (estimated by indirect calorimetry * physical activity factor) fats 28-35% carbohydrates 50-60% proteins 0,7-0,8g/kg of body weight 10-13% Diet will be given to the patient after the first visit and the study will start once the patient begins the diet.
Primary Outcome Measure Information:
Title
Change in disease related hormones
Description
Variation of GH, IGF-1, IGFBP1, IGFBP3 hormones
Time Frame
Change from Baseline GH, IGF-1, IGFBP1, IGFBP3 blood levels at 15 days, 30 days, 45 days, 60 days
Secondary Outcome Measure Information:
Title
Change in weight
Description
Variation of body weight assessed through body mass index change (BMI)(kg/m2)
Time Frame
Change from Baseline BMI at 15 days, 30 days, 45 days, 60 days
Title
Change in body circumferences
Description
Variation of body circumferences (waist, hips)
Time Frame
Change from Baseline circumferences at 15 days, 30 days, 45 dyas, 60 days
Title
Change in metabolic control
Description
Change of cardio-metabolic risk factors: lipid profile
Time Frame
Change from Baseline lipid profile at 15 days, 30 days, 45 days, 60 days
Title
Change in metabolic control
Description
Change of cardio-metabolic risk factors: insulin resistance (HOMA-IR)
Time Frame
Change from Baseline lipid profile at 60 days
Title
Change in kidney profile
Description
Variation of serum creatinin
Time Frame
Change from Baseline Serum Creatinin at 15 days, 30 days, 45 days, 60 days
Title
Change in liver profile
Description
Variation of liver markers(AST, ALT, GGT)
Time Frame
Change from Baseline Serum Creatinin at 15 days, 30 days, 45 days, 60 days
Title
Change in uric acid
Description
Variation of uric acid in blood through enzymatic determination
Time Frame
Change from Baseline uric acid in blood at 15 days, 30 days, 45 days, 60 days
Title
Change in body composition
Description
Change of body composition (fat mass %) (BIVA)
Time Frame
Change from Baseline fat mass% at 60 days
Title
Change in body composition
Description
Change of body composition (fat mass %) (DXA)
Time Frame
Change from Baseline fat mass% at 60 days
Title
Change in blood count
Description
Variation of blood count
Time Frame
Change from Baseline blood count at 15 days, 30 days, 45 days, 60 days
Title
Change in microbiota
Description
Variation of prevalence of microbiota phyla through DNA sequencing of stools
Time Frame
Change from Baseline of prevalence of microbiota phyla at 15, 30 days, 45 days, 60 days
Title
Change in omics profile
Description
Variation of lipidomic profile of stools through liquid and gas chromatography
Time Frame
Change from Baseline omic profile of stools at 15, 30 days, 45 days, 60 days
Title
Change in omics profile
Description
Variation of proteomic profile of stools through liquid and gas chromatography
Time Frame
Change from Baseline omic profile of stools at 15, 30 days, 45 days, 60 days
Title
Change in microvesicles
Description
Variation of urinary microvesicles levels
Time Frame
Change from Baseline microvesicles levels at 15, 30 days, 45 days, 60 days
Title
Change in microvesicles
Description
Variation of serum microvesicles levels
Time Frame
Change from Baseline microvesicles levels s at 15, 30 days, 45 days, 60 days
Title
Change in basal metabolic rate
Description
Variation of basal metabolic rate (kcal)
Time Frame
Change from Baseline basal metabolic rate at 60 days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age 18/65 Diagnosis of Acromegaly In therapy with somatostatin analogues Exclusion Criteria: pregnancy or lactation alchool or drugs abuse cancer Hematological diseases
Facility Information:
Facility Name
: Italy Pediatric Endocrine Service of AOU Maggiore della Carità of Novara; SCDU of Pediatrics, Department of Health Sciences, University of Eastern Piedmont
City
Novara
ZIP/Postal Code
28100
Country
Italy

12. IPD Sharing Statement

Plan to Share IPD
Undecided
Citations:
PubMed Identifier
34199514
Citation
Caputo M, Pigni S, Agosti E, Daffara T, Ferrero A, Filigheddu N, Prodam F. Regulation of GH and GH Signaling by Nutrients. Cells. 2021 Jun 2;10(6):1376. doi: 10.3390/cells10061376.
Results Reference
background
PubMed Identifier
9063764
Citation
Suminski RR, Robertson RJ, Goss FL, Arslanian S, Kang J, DaSilva S, Utter AC, Metz KF. Acute effect of amino acid ingestion and resistance exercise on plasma growth hormone concentration in young men. Int J Sport Nutr. 1997 Mar;7(1):48-60. doi: 10.1123/ijsn.7.1.48.
Results Reference
background
PubMed Identifier
18029456
Citation
van Vught AJ, Nieuwenhuizen AG, Brummer RJ, Westerterp-Plantenga MS. Effects of oral ingestion of amino acids and proteins on the somatotropic axis. J Clin Endocrinol Metab. 2008 Feb;93(2):584-90. doi: 10.1210/jc.2007-1784. Epub 2007 Nov 20.
Results Reference
background
PubMed Identifier
6269563
Citation
Sellini M, Fierro A, Marchesi L, Manzo G, Giovannini C. [Behavior of basal values and circadian rhythm of ACTH, cortisol, PRL and GH in a high-protein diet]. Boll Soc Ital Biol Sper. 1981 May 15;57(9):963-9. Italian.
Results Reference
background
PubMed Identifier
24606898
Citation
Levine ME, Suarez JA, Brandhorst S, Balasubramanian P, Cheng CW, Madia F, Fontana L, Mirisola MG, Guevara-Aguirre J, Wan J, Passarino G, Kennedy BK, Wei M, Cohen P, Crimmins EM, Longo VD. Low protein intake is associated with a major reduction in IGF-1, cancer, and overall mortality in the 65 and younger but not older population. Cell Metab. 2014 Mar 4;19(3):407-17. doi: 10.1016/j.cmet.2014.02.006.
Results Reference
background
PubMed Identifier
12433724
Citation
Allen NE, Appleby PN, Davey GK, Kaaks R, Rinaldi S, Key TJ. The associations of diet with serum insulin-like growth factor I and its main binding proteins in 292 women meat-eaters, vegetarians, and vegans. Cancer Epidemiol Biomarkers Prev. 2002 Nov;11(11):1441-8.
Results Reference
background
PubMed Identifier
15277169
Citation
Hoppe C, Udam TR, Lauritzen L, Molgaard C, Juul A, Michaelsen KF. Animal protein intake, serum insulin-like growth factor I, and growth in healthy 2.5-y-old Danish children. Am J Clin Nutr. 2004 Aug;80(2):447-52. doi: 10.1093/ajcn/80.2.447.
Results Reference
background
PubMed Identifier
31089868
Citation
Romo Ventura E, Konigorski S, Rohrmann S, Schneider H, Stalla GK, Pischon T, Linseisen J, Nimptsch K. Association of dietary intake of milk and dairy products with blood concentrations of insulin-like growth factor 1 (IGF-1) in Bavarian adults. Eur J Nutr. 2020 Jun;59(4):1413-1420. doi: 10.1007/s00394-019-01994-7. Epub 2019 May 14.
Results Reference
background
PubMed Identifier
24094144
Citation
Beasley JM, Gunter MJ, LaCroix AZ, Prentice RL, Neuhouser ML, Tinker LF, Vitolins MZ, Strickler HD. Associations of serum insulin-like growth factor-I and insulin-like growth factor-binding protein 3 levels with biomarker-calibrated protein, dairy product and milk intake in the Women's Health Initiative. Br J Nutr. 2014 Mar 14;111(5):847-53. doi: 10.1017/S000711451300319X. Epub 2013 Oct 7.
Results Reference
background
PubMed Identifier
25740607
Citation
Li R, Ferreira MP, Cooke MB, La Bounty P, Campbell B, Greenwood M, Willoughby DS, Kreider RB. Co-ingestion of carbohydrate with branched-chain amino acids or L-leucine does not preferentially increase serum IGF-1 and expression of myogenic-related genes in response to a single bout of resistance exercise. Amino Acids. 2015 Jun;47(6):1203-13. doi: 10.1007/s00726-015-1947-8. Epub 2015 Mar 5.
Results Reference
background
PubMed Identifier
32459928
Citation
Coopmans EC, Berk KAC, El-Sayed N, Neggers SJCMM, van der Lely AJ. Eucaloric Very-Low-Carbohydrate Ketogenic Diet in Acromegaly Treatment. N Engl J Med. 2020 May 28;382(22):2161-2162. doi: 10.1056/NEJMc1915808. No abstract available.
Results Reference
background

Learn more about this trial

Hypoproteic Diet in Acromegaly

We'll reach out to this number within 24 hrs